A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 31 Jan 2018
At a glance
- Drugs Durvalumab (Primary) ; MEDI 9090 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacodynamics
- Sponsors MedImmune
- 26 Jan 2018 Planned End Date changed from 9 Jan 2018 to 14 Feb 2019.
- 26 Jan 2018 Planned primary completion date changed from 9 Jan 2018 to 14 Feb 2019.
- 09 Mar 2017 Status changed from recruiting to active, no longer recruiting.